Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc.

Cezar Health is involved in the medical equipment and healthcare industry, providing products and services related to hospitals, dental units, and consumer health. The company self-described as a participant in various healthcare conferences and has launched its own private label brand in the health sector.

Cezar Health

Synergy CHC Corp is a consumer health care company. It is in the business of marketing and distributing consumer branded products through various distribution channels primarily in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Synergy generates the majority of its revenue from the sale of Flat Tummy Tea, which is exclusively sold online at www.flattummyco.com. Flat Tummy Tea is a uniquely formulated two-step herbal detox tea that works to naturally help speed metabolism, boost energy and reduce bloating.

Synergy CHC Corp.

Castle Biosciences develops innovative molecular diagnostics aimed at delivering personalized information to inform healthcare decisions. Their tests focus on melanoma metastasis risk and mental health medication profiles, among other areas.

Metric
Company Name	Castle Biosciences, Inc.	Cezar Health	Synergy CHC Corp.
Symbol	CSTL		SNYR
MSH ID	COM:CASTLEBIOSCIENCES	COM:CEZARHEALTH	COM:SYNERGYCHC
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services
Industry	Medical - Diagnostics & Research	Medical Equipment and Supplies
Country	US	PS	US
Stage
Employee Count	638		36
Website	castlebiosciences.com	cezarhealth.com	synergychc.com
LinkedIn			synergy-chc-corp
Founders

Metric
Market Cap	482.57M	48.48M
Enterprise Value
Monthly Web Traffic		1.76K
Web Traffic Growth		0.83
Valuation
Raised Capital		10M

Metric
Revenue	219.79M	42.78M
Revenue (LTM)
Revenue (NTM)
Gross Profit	164.23M	32.08M
EBITDA	-55.65M	10.84M
Operating Income	-67.98M	10.81M
Net Income	-57.47M	6.34M
EPS	-2.14	0.07
Diluted EPS	-2.14	0.07
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80	0.73
Operating Profit Margin	-0.05	0.19
EBITDA Margin	-0.25	0.25
Net Profit Margin	-0.01	0.06
Return on Equity	-0.01
Return on Assets	-0.01	0.07
Return on Capital Employed	-0.04	9.90

COM:CASTLEBIOSCIENCES

Castle Biosciences

Last Close

28.88

22/11 21:00

Market Cap

482.57M

Beta: -

Volume Today

314.82K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.33	-0.10
P/B Ratio	1.63	-0.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.28	12.31
EV Multiple	10.23K	59.33

Metric
Days Sales Outstanding	70.34	20.83
Days Payables Outstanding	60.10	1.05
Days Inventory Outstanding	60.83	375.05
Operating Cycle	124.44	469.08
Cash Conversion Cycle	50.86	469.08
Asset Turnover	0.59	1.43

Metric
Operating Cash Flow	-135K	421.73K
Free Cash Flow	-13.76M	421.73K
Cash Flow to Debt	4.12
Operating Cash Flow/Sales	0.16
Free Cash Flow Yield	-0.07	3.28

Metric
Cash & Equivalents	98.84M	632.53K
Accounts Receivable	-14.93M	1.38M
Inventory	7.94M	3.73M
Goodwill	10.69M
Debt to Capitalization	0.06	5.59
Debt to Assets	0.03	1.10
Current Ratio	7.70	0.50
Quick Ratio	9.02	0.76

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.26	0.01
R&D to Revenue	0.27
SG&A to Revenue	0.33	0.19